Lifecare ASA: Mandatory notification of trade allocation of subscription rights

07 Jan 2026 09:44 CET

Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 7 January 2026, regarding the commencement of the
subscription period in the partially underwritten rights issue (the "Rights
Issue").

In connection with the Rights Issue, subscription rights have been allocated
to existing shareholders as of 2 January 2026 (record date 6 January 2026),
based on their registered shareholdings in the Company. Each existing share
entitled the holder to 10.49 subscription rights, rounded down to the nearest
whole subscription right. Each subscription right gives the right to subscribe
for and be allocated one (1) new share in the Rights Issue at a subscription
price of NOK 0.50 per share.

Subscription rights have been allocated to the following primary insiders
and/or persons closely associated with them:

* Teigland Eiendom AS, a company closely associated with Trine Teigland, board
member of the Company, has been allocated 23,100,406 subscription rights.
* Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has been allocated 187,739 subscription rights.
* Tone Kvåle, board member of the Company, has been allocated 48,421
subscription rights.
* Joacim Holter, CEO of the Company, has been allocated 236,434 subscription
rights.
* Cimter AS, a company closely associated with Joacim Holter, CEO of the
Company, has been allocated 941,718 subscription rights.
* Islay Venture GmbH, a company closely associated with Andreas Pfützner, CSO
of the Company, has been allocated 1,410,747 subscription rights.

The allocation of subscription rights is made automatically and free of charge
to existing shareholders in accordance with the terms of the Rights Issue and
does not involve any consideration paid by the recipients.

Following the allocation of subscription rights, the shareholdings of the
above-mentioned primary insiders and/or their closely associated persons
remain unchanged.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-07 09:44 CET.

More information:
Access the news on Oslo Bors NewsWeb site

663191_Lifecare ASA- Mandatory notification of trade allocation of subscription rights.pdf